AI summary · may contain errors
In 33 patients with Fusobacterium nucleatum–positive, microsatellite-stable metastatic colorectal cancer, tislelizumab plus fruquintinib and metronidazole achieved a median progression-free survival of 6.0 months.
Moving in Journal of Clinical Oncology, JNCI: Journal of the National Cancer Institute, Annals of Oncology, Gastroenterology, Gut, Clinical Cancer Research, Frontiers in Genetics and JAMA Internal Medicine.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
In 33 patients with Fusobacterium nucleatum–positive, microsatellite-stable metastatic colorectal cancer, tislelizumab plus fruquintinib and metronidazole achieved a median progression-free survival of 6.0 months.
AI summary · may contain errors
In RAS/BRAF wild-type, left-sided metastatic colorectal cancer, m-FOLFOXIRI plus cetuximab improved median progression-free survival to 14.8 vs 11.9 months versus bevacizumab.
AI summary · may contain errors
Dynamic ctDNA methylation–guided surveillance in nonmetastatic colorectal cancer after curative resection increases curative-intent metastasis-directed therapy rates (48.1% vs 23.6%).
AI summary · may contain errors
Image-based consensus molecular subtyping (imCMS) of stage II/III colorectal cancer in the SCOT trial is strongly prognostic independent of clinicopathologic factors, dMMR, and CD8 IE -FoxP3 IS.
AI summary · may contain errors
Intermittent anti-EGFR treatment in left-sided, non–microsatellite instability high RAS and BRAF V600E wild-type metastatic colorectal cancer shows consistently lower anti-EGFR skin toxicity than maintenance.
AI summary · may contain errors
CADe device availability in Veterans Health Administration colonoscopy sites increased adenoma detection odds (OR 1.22, 95% CI 1.15–1.28) versus usual care.
AI summary · may contain errors
Census age- and sex-adjusted analysis of the PREEMPT CRC blood test shows nominally higher CRC sensitivity (81.1% vs 79.2%) in the evaluable cohort.
AI summary · may contain errors
Targeting DKK1 in second-line metastatic colorectal cancer did not significantly change treatment outcomes in the phase II DeFianCe trial.
AI summary · may contain errors
Bayesian spatial modeling of North Carolina multi-payer claims estimates colorectal cancer screening adherence for 1,180 ZIP-code areas, ranging from 43.1% to 93.1%.
AI summary · may contain errors
In nonmetastatic dMMR/MSI-H locally advanced lower rectal cancer, 13/13 per-protocol patients achieved clinical complete response and entered watch-and-wait after neoadjuvant sintilimab.
AI summary · may contain errors
Dostarlimab monotherapy in previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer achieved 68% sustained clinical complete response at 12 months (cCR12, investigator review).
AI summary · may contain errors
In high-risk stage III colon adenocarcinoma (pT4 and/or pN2) after R0 resection, adjuvant mFOLFIRINOX did not improve 3-year disease-free survival versus mFOLFOX6 (65.6% vs 66.3%).
AI summary · may contain errors
In advanced metastatic colorectal cancer, Temab-A 2.4 mg/kg plus bevacizumab achieved a 30% objective response rate and improved progression-free survival versus trifluridine-tipiracil plus bevacizumab.
AI summary · may contain errors
In Lynch syndrome patients with adenomas, 10-year CRC risk is higher for MLH1 than MSH2 carriers—7.9% vs 4.0% in males and 4.2% vs 1.6% in females.
AI summary · may contain errors
Low pretreatment inflammation-nutrition prognostic score (INPS < 0.058) is linked to higher objective response rate and pathological complete response in 312 locally advanced rectal cancer patients.
Journals this month
Topics moving, week to 18 Nov 2026
By field